Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 12/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23909497 | 1.00 | CA1 (0.45) | CA1CA2CA7MAPTCTSK | |
| SCHEMBL23909490 | 1.00 | CA1 (0.45) | CA1CA2CA7MAPTCTSK | |
| SCHEMBL1368733 | 0.87 | CA1 (0.45) | CA1CA2CA7MAPTCTSK | |
| SCHEMBL1368735 | 0.87 | CA1 (0.45) | CA1CA2CA7MAPTCTSK | |
| SCHEMBL23925242 | 0.81 | MAPT (0.43) | CA1CA2CA7MAPTCTSK | |
| SCHEMBL23925239 | 0.81 | MAPT (0.43) | CA1CA2CA7MAPTCTSK | |
| SCHEMBL23909481 | 0.81 | MAPT (0.43) | CA1CA2CA7MAPTCTSK | |
| SCHEMBL23909459 | 0.81 | MAPT (0.43) | CA1CA2CA7MAPTCTSK | |
| SCHEMBL23909460 | 0.81 | MAPT (0.43) | CA1CA2CA7MAPTCTSK | |
| SCHEMBL29508387 | 0.80 | CA1 (0.54) | CA1CA2CA7CTSKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398134-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240140946-A1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-05-02 | — | — | US | disclosed |
| US-11884662-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2024-01-30 | — | — | US | disclosed |
| EP-3802536-B1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210317116-A1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317116-A1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | IFNG, IFNAR1, CCL5 | CA1 4517/4885CA2 3926/4885CA7 3621/4885 |
| US-11884662-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IFNG, IFNAR1, CCL5 | CA1 4517/4885CA2 3926/4885CA7 3621/4885 |
| US-12398134-B2 | N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods | IFNG, IFNAR1, CCL5 | CA1 3905/4885CA2 3819/4885CA7 3499/4885 |
| US-20240140946-A1 | N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-c]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | IFNG, IFNAR1, CCL5 | CA1 3905/4885CA2 3819/4885CA7 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.